Your Source for Venture Capital and Private Equity Financings

Eliem Therapeutics Announces $60M Series B

2021-05-24
SEATTLE, WA, Eliem Therapeutics, a clinical-stage biotechnology company, has closed a $60M Series B financing led by Intermediate Capital Group and RA Capital.
SEATTLE, WA, Eliem Therapeutics, a clinical-stage biotechnology company, announced the closing of a $60 million Series B financing. The financing round was led by Intermediate Capital Group (ICG) and RA Capital Management and included participation from Access Biotechnology, Samlyn Capital, Acorn Bioventures and LifeArc.

Eliem Therapeutics is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading